ClinicalTrials.Veeva

Menu

Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers

Capital Medical University logo

Capital Medical University

Status and phase

Unknown
Phase 1

Conditions

Bacterial Conjunctivitis

Treatments

Drug: azithromycin eye drops by essex
Drug: azithromycin eye drops

Study type

Interventional

Funder types

Other

Identifiers

NCT03235141
ESSEX-AOS-PK-2001

Details and patient eligibility

About

To compare the pharmacokinetic behavior of azithromycin eye drops in the tear with the original azithromycin eye drops, and evaluate the release behavior of both in the eye.

Full description

There are 48 patients will divided into group A and group B randomly . subjects of Group A will given the first test drug, elution after the control drug; Subjects of Group B will given the first control drug, elution given to the test drug.

Enrollment

56 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • 18 to 65 years old, male or female;
  • BMI in the range of 19 to 28;
  • eyes corrected visual acuity should be ≥ 1.0, intraocular pressure, slit lamp and fundus examination were normal, tear secretion function is normal;
  • Good compliance and voluntarily signed consent.

Exclusion criteria

  • Have eye disease or systemic disease;
  • physical examination, laboratory tests, ECG and chest X-ray examination abnormalities and has clinical significance;
  • HBsAg, anti-HCV and HIV positive;
  • those who used eye drops two weeks before the test and who used any dosage form of azithromycin;
  • known to azithromycin or macrolide-related varieties of allergies or serious adverse reactions;
  • need to wear contact lenses during the test;
  • history of internal surgery or laser surgery history;
  • participated in other drug clinical trials in the past three months;
  • pregnant women and lactating women, or in the growth period without taking effective contraceptive measures, menstrual period women;
  • mental illness or alcohol, history of drug abuse or inability to collaborate;
  • Any other circumstances that the investigators consider are unfit to participate in this study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

56 participants in 2 patient groups

azithromycin eye drops by essex
Experimental group
Description:
In one cycle, give the azithromycin eye drops by essex,2.5ml/25mg,1 drop,once. In the second cycle(after 14 days elution),give the AzaSite eye drops,2.5ml/25mg,1 drop,once.
Treatment:
Drug: azithromycin eye drops by essex
Drug: azithromycin eye drops
AzaSite
Active Comparator group
Description:
In one cycle, give the AzaSite eye drops,2.5ml/25mg,1 drop,once. In the second cycle(after 14 days elution),give the azithromycin eye drops by essex,2.5ml/25mg,1 drop,once.
Treatment:
Drug: azithromycin eye drops by essex
Drug: azithromycin eye drops

Trial contacts and locations

1

Loading...

Central trial contact

Siyang Ni, Doctor; Xiuli Zhao, Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems